Abstract
Forty patients with familial hypercholesterolaemia (FH) were treated with 40 mg pravastatin once daily. Pravastatin decreased serum total and low density lipoprotein cholesterol (LDL) after 8 weeks of treatment by 28% and 33%, respectively, while high density lipoprotein cholesterol increased by 8% and triglycerides decreased by 14%. In 30 patients LDL cholesterol had not decreased below 5.0 mmol l-1 after 8 weeks of treatment, and in these patients resins were added to pravastatin, resulting in an additional decrease in total and LDL cholesterol of 8% and 12%, respectively. A control group of 22 FH patients was treated with placebo for 10 weeks, after which time resins were added, and they induced a decrease in total and LDL-cholesterol of 17% and 22%, respectively. Our results over a 24-week treatment period indicate that 40 mg pravastatin is more effective than 3 packets of resins in lowering LDL cholesterol, whereas the combination is most effective of all and can be used safely.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anticholesteremic Agents / adverse effects
-
Anticholesteremic Agents / therapeutic use
-
Bile Acids and Salts / therapeutic use*
-
Carrier Proteins / therapeutic use*
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
Heptanoic Acids / adverse effects
-
Heptanoic Acids / therapeutic use*
-
Humans
-
Hydroxysteroid Dehydrogenases*
-
Hyperlipoproteinemia Type II / drug therapy*
-
Male
-
Membrane Glycoproteins*
-
Naphthalenes / adverse effects
-
Naphthalenes / therapeutic use*
-
Pravastatin
-
Randomized Controlled Trials as Topic
-
Triglycerides / blood
Substances
-
Anticholesteremic Agents
-
Bile Acids and Salts
-
Carrier Proteins
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Heptanoic Acids
-
Membrane Glycoproteins
-
Naphthalenes
-
Triglycerides
-
bile acid binding proteins
-
Hydroxysteroid Dehydrogenases
-
AKR1C2 protein, human
-
Pravastatin